Intestinal Fatty Acid Binding Protein (I-FABP) as a Promising Test for Crohn's Disease: A Preliminary Study

Sarıkaya, Murat; Ergül, Bilal; Doğan, Zeynal; Filik, Levent; Çan, Murat; Arslan, Latife

doi:10.7754/clin.lab.2014.140518

Cited by 48 publications

(35 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…I-FABP can be elevated in other types of bowel disease, such as small bowel obstruction, mesenteric ischemia, acute enterocolitis, Crohn disease, ulcerative colitis, and necrotizing enterocolitis. [7,11,12,25–27] Besides these factors, I-FABP can increase the false-positive rate in trauma patients. First, hemorrhagic shock and systemic inflammatory response are known to cause intestinal mucosal damage.…”

Section: Discussionmentioning

confidence: 99%

Early diagnosis of hollow viscus injury using intestinal fatty acid–binding protein in blunt trauma patients

Matsumoto

Sekine

Funaoka³

et al. 2017

Medicine

View full text Add to dashboard Cite

A delay in diagnosing hollow viscus injury (HVI) causes an increase in mortality and morbidity. HVI remains a challenge to diagnose, and there is no specific diagnostic biomarker for HVI. We evaluated the utility of intestinal fatty acid–binding protein (I-FABP) in diagnosing HVI in blunt trauma patients. Within a 5-year period, 93 consecutive patients with clinically suspected HVI at our trauma center were prospectively enrolled. The diagnostic performance of I-FABP for HVI was compared with that of other various parameters (physical, laboratory, and radiographic findings). HVI was diagnosed in 13 patients (14%), and non-HVI was diagnosed in 80 patients (86%). The level of I-FABP was significantly higher in patients with HVI than in those with non-HVI (P = 0.014; area under the curve, 0.71). The sensitivity, specificity, positive predictive value, and negative predictive value were 76.9%, 70.0%, 29.4%, and 94.9%, respectively (P = 0.003). However, all other biomarkers were not significantly different between the groups. Presence of extraluminal air, bowel wall thickening on computed tomography (CT), and peritonitis signs were significantly higher in patients with HVI (P < 0.05). Of 49 patients (52.7%) who had a negative I-FABP and negative peritonitis signs, none developed HVI (sensitivity, 100%; negative predictive value, 100%). This is the first study that demonstrated the diagnostic value of a biomarker for HVI. I-FABP has a higher negative predictive value compared to traditional diagnostic tests. Although the accuracy of I-FABP alone was insufficient, the combination of I-FABP and other findings can enhance diagnostic ability.

show abstract

Section: Discussionmentioning

confidence: 99%

Early diagnosis of hollow viscus injury using intestinal fatty acid–binding protein in blunt trauma patients

Matsumoto

Sekine

Funaoka³

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

“…For this pilot study, we indirectly assessed gut permeability using markers of gut barrier dysfunction (FABP2) and immune activation secondary to gut microbial translocation (LBP, sCD14). These markers are associated with adverse outcomes in pathologic conditions characterized by increased gut permeability (e.g., liver cirrhosis, inflammatory bowel disease, HIV, and sepsis) (18,(25)(26)(27)(28). That FABP2, LBP, and sCD14 increase from pre-to postmenopause suggests that they are sensitive and precise enough to examine within-individual changes in gut physiology during the MT.…”

Section: L I N I C a L M E D I C I N Ementioning

confidence: 99%

Gut permeability, inflammation, and bone density across the menopause transition

Shieh¹,

Epeldegui²,

Karlamangla³

et al. 2020

JCI Insight

View full text Add to dashboard Cite

IntroductionInflammation contributes to the pathogenesis of numerous medical disorders that commonly affect older adults, including osteoporosis, diabetes mellitus, cardiovascular disease, and dementia (1-10); this is often referred to as inflammaging (3,11). Beyond chronological aging, the postmenopausal state may independently contribute to greater inflammation in older women. In animal models, chemical or surgical menopause leads to downregulation of epithelial junction proteins, gut barrier dysfunction, and increased gut permeability (12). This, in turn, permits the translocation of microbes from the intestinal lumen into the subepithelial space, triggering immune cells to produce proinflammatory cytokines (12). Whether an increase in gut permeability accompanies the menopause transition (MT) in humans is uncertain. If gut permeability does increase, whether it is associated with inflammation and end-organ manifestations is also unknown.The overarching goals of this pilot study were to determine if gut permeability increases during the MT and, if such an increase were confirmed, to explore whether gut permeability is associated with inflammation and bone mineral density (BMD). In this report, subsequent use of the term "gut permeability" refers to its indirect assessment using these blood markers. We used bone as a model end-organ system because increased gut permeability mediates inflammation and hypogonadal BMD loss in rodents, and probiotics that reduce gut permeability (12) or inflammation (13-15) can decrease bone resorption (12-15) and prevent bone loss (12, 15). Our primary hypothesis was that gut permeability increases from pre-to BACKGROUND. Inflammation is implicated in many aging-related disorders. In animal models, menopause leads to increased gut permeability and inflammation. Our primary objective was to determine if gut permeability increases during the menopause transition (MT) in women. Our exploratory objectives were to examine whether greater gut permeability is associated with more inflammation and lower bone mineral density (BMD). METHODS.We included 65 women from the Study of Women's Health Across the Nation (SWAN). Key measures were markers of gut permeability (gut barrier dysfunction, fatty acid binding protein 2 [FABP2]) and immune activation secondary to gut microbial translocation (LPS binding protein [LBP], soluble CD14 [sCD14]), inflammation (high-sensitivity CRP), and lumbar spine (LS) or total hip (TH) BMD. RESULTS.In our primary analysis, FABP2, LBP, and sCD14 increased by 22.8% (P = 0.001), 3.7% (P = 0.05), and 8.9% (P = 0.0002), respectively, from pre-to postmenopause. In exploratory, repeated measures, mixed-effects linear regression (adjusted for BMI, age at the premenopausal visit, race/ ethnicity, and study site), greater gut permeability was associated with greater inflammation, along with lower LS and TH BMD. CONCLUSION.Gut permeability increases during the MT. Greater gut permeability is associated with more inflammation and lower BMD. Future studies should examine the...

show abstract

“…A potential marker is intestinal fatty acid–binding protein (I‐FABP), a small (15 kDa), cytosolic, water‐soluble protein which is released upon enterocyte damage . Previous studies have identified serum I‐FABP as a marker of acute intestinal ischemia, necrotizing enterocolitis, sepsis, and Crohn's disease . I‐FABP has also been examined as a marker in CD diagnostics and is both significantly elevated in CD patients and correlates with the degree of mucosal damage .…”

mentioning

confidence: 99%

Serum intestinal fatty acid–binding protein in the noninvasive diagnosis of celiac disease

Oldenburger

Wolters

Kardol‐Hoefnagel

et al. 2018

APMIS

View full text Add to dashboard Cite

Current diagnostic guidelines for celiac disease (CD) in pediatric patients require a duodenal biopsy if the IgA anti-tissue transglutaminase (tTG) is below 10x the upper limit of normal (ULN). Additional markers may enable a noninvasive diagnosis in this group. Serum intestinal-fatty acid-binding protein (I-FABP), a marker for intestinal epithelial damage, could be useful in this respect. A total of 95 children with a clinical suspicion of CD and tTG 1-10x ULN were investigated. All had a duodenal biopsy and analysis of serum I-FABP. A control group of 161 children with familial short stature and normal tTG was included. I-FABP levels in the 71 patients with tTG 1-10x ULN and biopsy-proven CD (median 725 pg/mL) were not significantly different (p = 0.13) from the levels in the 24 patients with a tTG 1-10x ULN but a normal biopsy (median 497 pg/mL). However, when combining tTG and I-FABP levels, 11/24 patients could have been diagnosed noninvasively if tTG is ≥ 50 U/mL and I-FABP ≥880 pg/mL or in 12/19 patients if tTG is ≥ 60 U/mL and I-FABP ≥ 620 pg/mL. Therefore, addition of I-FABP to the diagnostic procedure of CD may provide a noninvasive diagnosis in patients with a tTG ≥ 50 U/mL.

show abstract

Intestinal Fatty Acid Binding Protein (I-FABP) as a Promising Test for Crohn's Disease: A Preliminary Study

Cited by 48 publications

References 0 publications

Early diagnosis of hollow viscus injury using intestinal fatty acid–binding protein in blunt trauma patients

Early diagnosis of hollow viscus injury using intestinal fatty acid–binding protein in blunt trauma patients

Gut permeability, inflammation, and bone density across the menopause transition

Serum intestinal fatty acid–binding protein in the noninvasive diagnosis of celiac disease

Contact Info

Product

Resources

About